Trillions of dollars are being invested in developing hundreds of mRNA “vaccines” and other mRNA-based “therapies.” Our society has reached “Peak Insanity.”
JAMES ROGUSKI
Moderna has dozens of mRNA “vaccines” in their development pipeline:
- mRNA-1010 (Flu) CLINICAL TRIAL NCT05606965
- mRNA-1011 (Flu) CLINICAL TRIAL NCT05827068
- mRNA-1012 (Flu) CLINICAL TRIAL NCT05827068
- mRNA-1018 (Pandemic Flu) CLINICAL TRIAL NCT05972174
- mRNA-1020 (Flu) CLINICAL TRIAL NCT05333289
- mRNA-1030 (Flu) CLINICAL TRIAL NCT05333289
- mRNA-1045 (Flu + RSV vaccine) CLINICAL TRIAL NCT05585632
- MRNA-1073 (COVID + FLU) CLINICAL TRIAL NCT05375838
- mRNA-1083 (Flu + COVID vaccine) CLINICAL TRIAL NCT06694389
- mRNA-1189 (EBV vaccine to prevent infectious mononucleosis) CLINICAL TRIAL NCT05164094
- mRNA 1195 (EBV vaccine to address EBV sequelae) CLINICAL TRIAL NCT05831111
- mRNA-1215 (Nipah vaccine) CLINICAL TRIAL NCT05398796
- mRNA-1230 (Flu + COVID + RSV vaccine) CLINICAL TRIAL NCT05585632
- mRNA-1273 (COVID-19 vaccine Spikevax®)
- mRNA-1273.815 (COVID-19 vaccine adolescents)
- mRNA-1273.815 (COVID-19 vaccine pediatrics)
- mRNA-1287 (Endemic HCoV Human Coronavirus vaccine)
- mRNA-1283 (COVID-19 vaccine Next gen) CLINICAL TRIAL NCT05137236
- mRNA-1345 (RSV mRESVIA® Respiratory syncytial virus vaccine older adults)
- mRNA-1345 (RSV Respiratory syncytial virus vaccine pediatrics) CLINICAL TRIAL NCT06143046
- mRNA-1365 (RSV + hMPV Human MetaPneumoVirus vaccine) CLINICAL TRIAL NCT05743881
- mRNA-1403 (Norovirus vaccine) CLINICAL TRIAL NCT06592794
- mRNA-1405 (Norovirus vaccine) CLINICAL TRIAL NCT05992935
- mRNA-1468 (VZV Varicella-zoster virus chickenpox/shingles vaccine) CLINICAL TRIAL NCT05701800
- mRNA-1574 (HIV vaccine)
- mRNA-1608 (HSV Herpes Simplex Virus vaccine) CLINICAL TRIAL NCT06033261
- mRNA-1644 (HIV Vaccine) CLINICAL TRIAL NCT05001373
- mRNA-1647 (Cytomegalovirus (CMV) vaccine) CLINICAL TRIAL NCT05085366
- mRNA-1769 (Mpox vaccine) CLINICAL TRIAL NCT05995275
- mRNA-1893 (Zika vaccine) CLINICAL TRIAL NCT04917861
- mRNA-1975 (Lyme Vaccine) CLINICAL TRIAL NCT05975099
- mRNA-1982 (Lyme Vaccine) CLINICAL TRIAL NCT05975099
CANCER THERAPIES:
- mRNA-2752 (OX40L/IL-23/IL-36γ (Triplet) Solid tumors/lymphoma) CLINICAL TRIAL NCT03739931
- mRNA-4157 (Individualized neoantigen therapy (INT) adjuvant melanoma)
- mRNA-4157 (Individualized neoantigen therapy (INT) – adjuvant NSCLC)
- mRNA-4157 (Individualized neoantigen therapy (INT) – adjuvant NSCLC post neoadjuvant treatment)
- mRNA-4157 (Individualized neoantigen therapy (INT) – cutaneous squamous cell carcinoma (cSCC))
- mRNA-4157 (Individualized neoantigen therapy (INT) – renal cell carcinoma (RCC))
- mRNA-4157 (Individualized neoantigen therapy (INT) – adjuvant non-small cell lung cancer (NSCLC))
- mRNA-4157 (Individualized neoantigen therapy (INT) – early and late solid tumor (first in human)) CLINICAL TRIAL NCT03313778
- mRNA-4157 (Individualized neoantigen therapy (INT) – renal cell carcinoma (RCC))
- mRNA-4157 (Individualized neoantigen therapy (INT) – bladder cancer)
- mRNA-4359 (Checkpoint vaccine) CLINICAL TRIAL NCT05533697
- mRNA-5671 (KRAS vaccine) CLINICAL TRIAL NCT03948763
OTHER DISEASES:
- mRNA-0184 Relaxin CLINICAL TRIAL NCT06655870
- mRNA-3139 Ornithine transcarbamylase deficiency (OTC)
- mRNA-3210 Phenylketonuria (PKU) CLINICAL TRIAL NCT06147856
- mRNA-3351 Crigler-Najjar Syndrome Type 1 (CN-1)
- mRNA-3692 Cystic Fibrosis (CF)* / VX-522
- mRNA-3705 Methylmalonic acidemia (MMA) CLINICAL TRIAL NCT04899310
- mRNA-3745 Glycogen storage disease Type 1a (GSD1a) CLINICAL TRIAL NCT05095727
- mRNA-3927 Propionic Acidemia (PA) CLINICAL TRIAL NCT04159103
https://www.modernatx.com/en-US/research/product-pipeline
https://investors.modernatx.com/events-and-presentations/Program-Detail/default.aspx
CureVac
A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older
GlaxoSmithKline
A Study on the Safety, Reactogenicity and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults
GlaxoSmithKline’s (GSK) messenger RNA (mRNA)-based monovalent vaccine(GSK4382276A) candidate against influenza in healthy younger adults (YA) and older adults (OA).
GSK/CureVac’s GSK4382276 and GSK4388067
Influenza and, separately, COVID-19
GSK is also targeting both influenza and COVID-19, though currently with separate products. In July, the British multinational bought the global rights to develop CureVac’s investigational mRNA vaccines against COVID-19 (GSK4388067) and influenza (GSK4382276), with the option to develop a combination and an additional vaccine against avian flu. GSK4388067 and GSK4382276 are both currently in Phase II trials and are therefore not too far behind their rivals.
Hans W. Nijman, MD PHD, University Medical Center Groningen
Ovarian Cancer Treatment With a Liposome Formulated mRNA Vaccine in Combination With (Neo-)Adjuvant Chemotherapy (OLIVIA)
National Institute of Allergy and Infectious Diseases (NIAID)
Dose Escalation, Open-Label Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of a Nipah Virus (NiV) mRNA Vaccine, mRNA-1215, in Healthy Adults
National Institute of Allergy and Infectious Diseases (NIAID)
A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults
In May 2023, NIAID started enrolling participants in a phase 1 trial studying a universal flu vaccine that uses mRNA technology.
National Institute of Allergy and Infectious Diseases (NIAID)
A Clinical Trial to Evaluate the Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines in Healthy, HIV-uninfected Adult Participants
Pfizer
A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older
Ruijin Hospital
Mechanistic Study of EBV mRNA Vaccine (WGc-043) in EBV-Positive Relapsed/Refractory Lymphoma (WGc-043)
Sanofi Pasteur, a Sanofi Company
A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older.
Shanghai Jiao Tong University School of Medicine
Treatment of Advanced Endocrine Tumor With Individualized mRNA Neoantigen Vaccine (mRNA-0523-L001)
Stemirna Therapeutics
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Esophageal Cancer and Non-small Cell Lung Cancer
The information listed above is merely a drop in the bucket.
James Roguski
310-619-3055
JamesRoguski.substack.com/archive
Please help spread the word about the harmful effects of the mRNA bioweapons:
NotSafeAndNotEffective.com
CullingIsMurder.com
PCRfraud.com
MaskCharade.com
StopTheGlobalAgenda.com
I claim no copyright of any kind whatsoever, over any of my work, ever. Everyone is encouraged to copy any and all of it, in part, or in full, and use it for whatever purposes they wish. In fact, I would be delighted if someone were to copy this entire body of work. I encourage everyone to duplicate and mirror it in its entirety. I also encourage everyone to adapt and utilize the information in whatever manner they deem appropriate. No citation or other reference is requested or required. It would actually bring me great joy to see this information multiply exponentially and “go viral”.
All content is free to all readers.
All support is deeply appreciated.
CLICK HERE TO DONATE
This article (mRNA Products in the Development Pipeline) was created and published by James Roguski and is republished here under “Fair Use”
Featured image: seekingalpha.com
••••
The Liberty Beacon Project is now expanding at a near exponential rate, and for this we are grateful and excited! But we must also be practical. For 7 years we have not asked for any donations, and have built this project with our own funds as we grew. We are now experiencing ever increasing growing pains due to the large number of websites and projects we represent. So we have just installed donation buttons on our websites and ask that you consider this when you visit them. Nothing is too small. We thank you for all your support and your considerations … (TLB)
••••
Comment Policy: As a privately owned web site, we reserve the right to remove comments that contain spam, advertising, vulgarity, threats of violence, racism, or personal/abusive attacks on other users. This also applies to trolling, the use of more than one alias, or just intentional mischief. Enforcement of this policy is at the discretion of this websites administrators. Repeat offenders may be blocked or permanently banned without prior warning.
••••
Disclaimer: TLB websites contain copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of “fair use” in an effort to advance a better understanding of political, health, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than “fair use” you must request permission from the copyright owner.
••••
Disclaimer: The information and opinions shared are for informational purposes only including, but not limited to, text, graphics, images and other material are not intended as medical advice or instruction. Nothing mentioned is intended to be a substitute for professional medical advice, diagnosis or treatment.
Disclaimer: The views and opinions expressed in this article are those of the author and do not necessarily reflect the official policy or position of The Liberty Beacon Project.
Leave a Reply